Appendix Table 5.

One-Way Sensitivity Analyses: Individualized Versus Uniform Intensive Control

Scenario	Incremental Lifetime Costs, $*	Incremental Life-Years	Incremental QALYs
Medication changes HbA1c level
By 1.2%	−12 574	−0.17	0.06
By 0.8%	−12 520	−0.08	0.14
Medication increases hypoglycemic event rates
By 20% more	−13 443	−0.11	0.10
By 20% less	−13 376	−0.09	0.10
Severe hypoglycemia increases health care use
By 20% more	−13 983	−0.16	0.06
By 20% less	−12 911	−0.16	0.06
Costs of microvascular complications
20% more	−12 993	−0.13	0.07
20% less	−13 228	−0.09	0.11
Costs of macrovascular complications
20% more	−13 739	−0.14	0.08
20% less	−13 443	−0.10	0.11
Costs of hypoglycemic events
20% more	−13 675	−0.13	0.08
20% less	−13 182	−0.10	0.10
Costs of diabetes medications
20% more	−15 504	−0.08	0.12
20% less	−10 084	−0.12	0.09
Disutility due to microvascular complications
20% more	−13 373	−0.10	0.10
20% less	−13 404	−0.08	0.04
Disutility due to macrovascular complications
20% more	−13 560	−0.11	0.11
20% less	−13 600	−0.16	0.08
Disutility due to hypoglycemic events
20% more	−13 295	−0.10	0.10
20% less	−13 134	−0.12	0.10
Discount rate
1% annually	−13 826	−0.12	0.09
5% annually	−12 563	−0.09	0.11
Combination of utilities: additive method	Not applicable	Not applicable	0.12

HbA_1c = glycated hemoglobin; QALY = quality-adjusted life-year.

^*Expressed in 2015 U.S. dollars. Negative values indicate cost savings from individualized vs. uniform intensive control.